Siemens Healthcare Diagnostics Products Gmbh

Siemens Healthcare Diagnostics Gmbh

Siemens Healthcare Gmbh

Siemens Healthcare Diagnostics Holding Gmbh

Herbert Schwarz

Andreas Keller

Harald Althaus

Frank Vitzthum

Norbert F Zander

Thomas Wissel

Andreas Kappel

William D Bedzyk

Bodo Fischer

Gerlinde Christ

Cord Friedrich Stähler

Anja Haude-Barten

Katharina Dekevic

Michaela Wicke

Ian Wright

Linda Marie Anderson-Mauser

A method and kit are provided herein for determining the ADAMTS-13 activity in a sample. The method comprises contacting the sample with a von Willebrand factor (VWF) polypeptide which has been coupled to a reporter enzyme, such as glucose-6-phosphate dehydrogenase (G6PDH).

Enzyme-enhanced ADAMTS-13 activity assay

The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses Fc&#x3b3;RIIa protein-coated particles.

Binding assay for the diagnosis of a heparin-induced thrombocytopenia

The present invention relates to a functional, easily automatable assay for establishing a heparin-induced thrombocytopenia (HIT). What is measured is the secretion of PF4 (platelet factor 4) from activated thrombocytes.

Activation assay for the diagnosis of a heparin-induced thrombocytopenia

Methods for detection and quantitative measurement of proteins with a Coomassie Brilliant Blue Assay with improved sensitivity and maintaining high linearity over a broad measuring range are provided herein. In particular, a method of detecting a protein in a protein-containing sample is provided. The method includes providing a sample including a protein, a reagent including Coomassie Brilliant Blue and having a pH between 0.85 and 1.1, combining the sample and the reagent, and determining absorption at first and second wavelength to determine the amount of protein in the sample. The ratio of the absorption value at the first wavelength between about 580 to 620 nm to the absorption value at the second wavelength between about 520 to 370 nm is used in the spectral photometric determination of the amount of protein.

Coomassie Brilliant Blue Assay with improved sensitivity

A homogeneous method for determining the enzymatic activity of an analyte in a sample permits simultaneous determination of the amount of enzyme in the same reaction mixture and determination of enzyme activators or inhibitors.

Homogeneous activity test for determining enzymatic reactions

The invention relates to peptides with the Marburg I polymorphism of FSAP and to their preparation and uses, in particular in therapy and diagnosis. The peptides are suitable for use as immunizing antigens for preparing FSAP MR I specific antibodies.

Peptides with the marburg I polymorphism of factor VII-activating protease (FSAP) and their preparation and uses

The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP). The heterozygous or homozygous presence of an MR I polymorphism can be identified by a differential modulation of the FSAP activity.

Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity

The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein or other mutant variants which are characterized by amino acid substitutions at other positions in the FSAP protein.

Growing community of inventors

Lohra, Germany

Herbert Schwarz